Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Serum Institute to...

    Serum Institute to come up with coronavirus vaccine by 2022

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-02-21T12:13:16+05:30  |  Updated On 21 Feb 2020 12:13 PM IST
    Serum Institute to come up with coronavirus vaccine by 2022

    The vaccine candidate, developed by SII in partnership with American biotechnology firm Codagenix, has progressed to the pre-clinical test phase (the animal trial phase) and we hope to be ready with the vaccine by early 2022

    Pune: City-based Serum Institute of India (SII) on Wednesday said it expects to be ready with a vaccine against the novel coronavirus (COVID-19) by early 2022.

    SII announced that a vaccine candidate for the novel coronavirus, which has killed more than 2,000 people in China since its outbreak in December-end, is expected to progress to human trial phase within the next six months.

    "The vaccine candidate, developed by SII in partnership with American biotechnology firm Codagenix, has progressed to the pre-clinical test phase (the animal trial phase) and we hope to be ready with the vaccine by early 2022," SII CEO Adar Poonawalla said in a statement here.

    "The combined efforts with the team at Codagenix have borne fruit and we hope to save millions of lives with this vaccine," he said.

    The statement said since the novel coronavirus has affected the lives of thousands of people on the planet, a preventive measure has become a necessity.

    "While several efforts have been made to finding a cure as well as in controlling the outbreak, this is the first vaccine-virus strain to progress to the pre-clinical trial phase," the company said.

    The vaccine-virus strain is identical to the original virus and can generate a robust immune response, Poonawalla said.

    The vaccine-virus strain will be the fastest such Made in India vaccine to progress to the human trials phase within six months, he said.

    The cost of the project is up to Rs 300 crore, for which SII aims to secure external funding via various global partners, he said.

    Poonawalla said they are in talks with several firms across the globe for potential partnerships.

    "We are not excluding China as a potential site for our clinical trials. By August-end, we will have data on mice and primates to submit to regulatory authorities to enter into the human trials phase," he said.

    SII is the world's largest vaccine manufactured by a number of doses produced and sold globally, with more than 1.5 billion doses so far.

    Read also: Serum Institute unveils new rotavirus vaccine Rotasiil-Liquid to prevent diarrhoea

    coronavirusserum-institutecovid-19codagenixadar-poonawallaserum-institute-india
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok